Compare BIO-TECHNE Corp (TECH) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs iShares 10 20 Year Treasury Bond ETF — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while iShares 10 20 Year Treasury Bond ETF trades at $96.55. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while iShares 10 20 Year Treasury Bond ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| TECH | TLH | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Fixed Income |
52-Week High | $72.29 | $105.36 |
52-Week Low | $43.31 | $96.39 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
TLH trades at $97.05 with minimal daily movement (+0.23%), showing technical bearish signals from moving averages while oscillators remain neutral. The stock maintains consistent dividend payments, with recent payouts of $0.41, $0.36, and $0.38 per share. Market sentiment reflects broader bond market concerns as Treasury yields rise amid inflation uncertainty and geopolitical tensions.
The outlook remains cautious with bearish technical indicators dominating and macroeconomic pressures from rising interest rates. Dividend stability provides some support, but the stock faces headwinds from bond market volatility and inflation concerns that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
